Liquidia Corp LQDA
Institutional shares held
47.5 Million
1.61M
calls
1.15M
puts
Total value of holdings
$1.09B
$37M
calls
$26.3M
puts
Market Cap
$1.48B
64,362,300
Shares Out.
Institutional ownership
73.72%
# of Institutions
209
We take great care to ensure that the data presented and summarized in this overview for Liquidia Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LQDA
View all-
Black Rock Inc. New York, NY4.24MShares$97.3 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.24MShares$97.3 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$82.5 Million0.0% of portfolio
-
Findell Capital Management LLC New York, NY3MShares$68.9 Million18.2% of portfolio
-
Opaleye Management Inc. Boston, MA2.48MShares$56.8 Million7.37% of portfolio
-
Goldman Sachs Group Inc New York, NY2.42MShares$55.5 Million0.0% of portfolio
-
State Street Corp Boston, MA1.83MShares$42 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.63MShares$37.5 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.62MShares$37.1 Million0.46% of portfolio
-
Geode Capital Management, LLC Boston, MA1.41MShares$32.3 Million0.0% of portfolio
Latest Institutional Activity in LQDA
Top Purchases
Top Sells
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Insider Transactions at LQDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2025
|
Raman Singh Director |
SELL
Open market or private sale
|
Direct |
45,524
-59.29%
|
$1,138,100
$25.81 P/Share
|
|
Sep 15
2025
|
Raman Singh Director |
BUY
Exercise of conversion of derivative security
|
Direct |
45,524
+25.84%
|
$91,048
$2.55 P/Share
|
|
Sep 03
2025
|
Raman Singh Director |
SELL
Open market or private sale
|
Direct |
7,500
-19.35%
|
$217,500
$29.42 P/Share
|
|
Sep 02
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
1,148
-0.32%
|
$33,292
$29.05 P/Share
|
|
Sep 02
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
1,063
-0.18%
|
$30,827
$29.05 P/Share
|
|
Sep 02
2025
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
70,692
-10.81%
|
$1,979,376
$28.76 P/Share
|
|
Sep 02
2025
|
Paul B Manning |
SELL
Open market or private sale
|
Indirect |
328,268
-24.08%
|
$9,191,504
$28.91 P/Share
|
|
Sep 02
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
451
-0.26%
|
$13,079
$29.05 P/Share
|
|
Aug 29
2025
|
Dana Boyle Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
296
-0.16%
|
$8,584
$29.05 P/Share
|
|
Aug 29
2025
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.65%
|
-
|
|
Aug 29
2025
|
Sarah Krepp Chief Human Resource Officer |
SELL
Open market or private sale
|
Direct |
209
-0.15%
|
$6,061
$29.05 P/Share
|
|
Aug 29
2025
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+0.4%
|
-
|
|
Aug 29
2025
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+0.82%
|
-
|
|
Aug 29
2025
|
Paul B Manning |
SELL
Open market or private sale
|
Indirect |
188,232
-19.87%
|
$5,082,264
$27.62 P/Share
|
|
Aug 29
2025
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,562
+0.89%
|
-
|
|
Aug 28
2025
|
Paul B Manning |
SELL
Open market or private sale
|
Indirect |
154,337
-14.01%
|
$4,167,099
$27.94 P/Share
|
|
Aug 28
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-7.41%
|
$540,000
$27.85 P/Share
|
|
Aug 28
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
26,057
-13.22%
|
$703,539
$27.86 P/Share
|
|
Aug 19
2025
|
Joanna Horobin Director |
SELL
Open market or private sale
|
Direct |
5,000
-12.9%
|
$135,000
$27.17 P/Share
|
|
Aug 15
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
20,000
-5.31%
|
$520,000
$26.18 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.15M
Shares
From
24
Insiders
| Grant, award, or other acquisition | 845K shares |
|---|---|
| Exercise of conversion of derivative security | 303K shares |
| Open market or private sale | 459 shares |
Sell / Disposition
1.21M
Shares
From
11
Insiders
| Open market or private sale | 1.21M shares |
|---|